Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

THR-687, a potent small molecule integrin receptor antagonist, holds promise as a therapeutic approach for back-of-the-eye vascular pathologies

Inge Van Hove, Marc Vanhove, Michael Porcu, Tjing-Tjing Hu, Bart Jonckx, Philippe Barbeaux, Jean HM Feyen, Elke Vermassen. THR-687, a potent small molecule integrin receptor antagonist, holds promise as a therapeutic approach for back-of-the-eye vascular pathologies. 2017

Publication date: 
June, 2017